share_log

The Analyst Verdict: IGM Biosciences In The Eyes Of 5 Experts

The Analyst Verdict: IGM Biosciences In The Eyes Of 5 Experts

分析師的觀點:igm biosciences在5位專家眼中
Benzinga ·  09/05 10:00
Ratings for IGM Biosciences (NASDAQ:IGMS) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去的三個月中,IGm Biosciences (納斯達克股票代碼: IGMS)的評級來自5位分析師,展示了看好和看淡的觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估,下表展示了過去30天內不斷變化的情緒,並將其與之前的幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $18.4, a high estimate of $25.00, and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 4.55% increase from the previous average price target of $17.60.
The 12-month price targets, analyzed by analysts, offer insights with an average target of $18.4, a high estimate of $25.00, and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 4.55% increase from the previous average price target of $17.60.
Decoding Analyst Ratings: A Detailed Look
分析師評級解讀:詳細解析
An in-depth analysis of recent analyst...
最近對IGm生...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論